Abbott Rapid DX North America LLC

Abbott Rapid DX North America LLC, doing business as Alere North America LLC, supplies point-of-care diagnostic testing devices, rapid antigen tests, and molecular diagnostic platforms to federal healthcare agencies as a prime contractor across full-and-open competitive procurements with no set-aside designations. The Lake Mary, Florida-based entity is a subsidiary of Abbott Laboratories Inc., itself owned by Alere Inc.; the vendor competes exclusively in the open market and carries no SBA certifications. Abbott Rapid DX operates primarily under NAICS 424210 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers) and PSC Group 66 (Laboratory Equipment and Supplies), with secondary activity in in vitro diagnostic substance manufacturing.

Abbott Rapid DX's federal footprint centers on COVID-19 and infectious-disease point-of-care testing. Representative capability work includes a $2.52 million definitive contract awarded by the Defense Health Agency on October 1, 2025, for Abbott ID NOW molecular analyzers and reagents through September 2030; a $30 million indefinite delivery contract from the Defense Logistics Agency awarded February 9, 2026, for laboratory equipment and supplies to federal laboratories nationwide; and hundreds of delivery orders from the Defense Logistics Agency Medical Supply Chain for BinaxNOW COVID-19 antigen test cards, ID NOW rapid diagnostic tests for strep and influenza, COVID-19 test kits, and AFINION hemoglobin A1C testing consumables, typically valued $600 to $69,600 per order. Additional recent work includes an $82,304 purchase order from Veterans Integrated Service Network 10 for Abbott ID NOW analyzers and test kits under a one-year promotional arrangement (July 2026), and a $243.2 million single-award indefinite delivery contract from Veterans Integrated Service Network 4 for A1C point-of-care testing services through April 2030.

Customer concentration is extreme and skewed toward Department of Defense procurement. The Defense Logistics Agency Troop Support Medical component accounts for 1,692 awards (82% of recent awards) valued at $5.36 billion combined potential value—roughly 68% of the vendor's entire $7.9 billion federal footprint. The top five funding agencies account for 82% of awards: the DLA Medical Supply Chain dominates both by volume and dollars, followed at substantial distance by the Indian Health Service (77 awards, $174.7 million), Veterans Integrated Service Network 4 (50 awards, $5.9 million), VISN 17 (49 awards, $4.3 million), and VISN 16 (47 awards, $7.2 million). By potential value, the DLA's dominance widens further—the second-ranked customer, Veterans Integrated Service Network 12, claims only $335.7 million against the DLA's $5.36 billion. Abbott Rapid DX also holds a General Services Administration Schedule 65-VII contract for in vitro diagnostics, reagents, and tests, through which it fields task orders for COVID-19 testing supplies across multiple VA service networks.

Abbott Rapid DX's primary parent vehicle is the DLA indefinite delivery contract SPE2DE21D0017, through which 1,455 delivery orders have been issued totaling $7.7 million in combined ceiling value. The vendor also places work under GSA Schedule 65-VII (453 task orders, $77.2 million), DLA contract SPE2DE20D0027 (165 task orders, $937.8 million), and a 2025 VISN 4 single-award IDC for A1C testing ($243.2 million ceiling). Recent activity shows marked deceleration: Abbott Rapid DX received 314 awards in 2022 and 396 in 2023, declining to 355 in 2024, 264 in 2025, and only 71 in the first seven months of 2026. In the next twenty-four months, only seven awards face ultimate completion and potential recompete, representing $1.3 million in combined ceiling value—a low near-term recompete risk relative to the vendor's scale.

Abbott Rapid DX operates almost entirely as a prime contractor (2,340 of 2,346 awards); minimal subcontract exposure appears as a sub-recipient to Cardinal Health 200, LLC on a medical-surgical supplies award (March 2022) and to the Louisiana Department of Health on a COVID-19 test sub-award (March 2024). The vendor's award portfolio is heavily concentrated in laboratory equipment and supplies (1,748 awards), in vitro diagnostic substances (255 awards), and medical and surgical instruments (209 awards). Abbott Rapid DX North America LLC maintains its geographic footprint in Lake Mary, Florida for most contract performance, with a secondary location identified in Lockhart, Florida for some Defense Logistics Agency work. The parent company structure—Abbott Laboratories Inc. as ultimate parent—provides substantial financial backing and access to Abbott's global diagnostic and medical device ecosystem, though federal procurement is conducted through the Rapid DX subsidiary.